Effects on musculoskeletal system

See also: Musculoskeletal adverse events

Retrospective studies

Antoniou T, Macdonald EM, Yao Z, et al. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. BMC Musculoskelet Disord. 2018. doi:10.1186/s12891-018-2076-9 • PubMed

Lin WL, Hsieh YW, Lin CL, Sung FC, Wu CH, Kao CH. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia. Clin Endocrinol. 2015. doi:10.1111/cen.12599 • PubMed

Welk B, McArthur E, Ordon M, Dirk J, Dixon S, Garg AX. Risk of rhabdomyolysis from 5-α reductase inhibitors. Pharmacoepidemiol Drug Saf. 2018. doi:10.1002/pds.4383 • PubMed

Case reports

Al-Harbi TM, Kagan J, Tarnopolsky MA. Finasteride-induced myalgia and HyperCKemia. J Clin Neuromuscul Dis. 2008. doi:10.1097/CND.0b013e3181873cca • PubMed

Haan J, Hollander JM, van Duinen SG, Saxena PR, Wintzen AR. Reversible severe myopathy during treatment with finasteride. Muscle Nerve. 1997. DOI • PubMed

Persey M, Payne L, Webley M. Finasteride: a steroid-unsparing drug? Rheumatology (Oxford). 1999. doi:10.1093/rheumatology/38.3.285PubMed

Ryu HJ, Kwon DY. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia. Dermatol Surg. 2014. doi:10.1111/dsu.12458

Smith VM, Cockshoot D. A serious side effect of a potentially widely used cosmetic product. Clin Exp Dermatol. 2015. doi:10.1111/ced.12570 • PubMed

Letter

Sirufo MM, Ginaldi L, De Martinis M. Bone health risks associated with finasteride and dutasteride long-term use [Letter]. World J Mens Health. 2020. doi:10.5534/wjmh.200138

Clinical trials

💊 [Funded by GlaxoSmithKline] Amory JK, Anawalt BD, Matsumoto AM, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol. 2008. doi:10.1016/j.juro.2008.01.145

💊 [Received support from Merck] Borst SE, Yarrow JF, Conover CF, et al. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab. 2014. doi:10.1152/ajpendo.00592.2013 • PMC full text

💊 [Funded by Merck] Matsumoto AM, Tenover L, McClung M, et al; PLESS Study Group. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002. PubMed